Bisphosphonates for malignancy-related bone disease: Current status, future developments

Supportive Care in Cancer

Volumn 14, Issue 5, 2006, Pages 408-418

  Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant; Bisphosphonates; Bone metastases; Ibandronate; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; IBANDRONIC ACID; LETROZOLE; OPIATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ESOPHAGITIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; INJECTION SITE REACTION; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 33646444443     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0913-5     Document Type: Review

References (89)

1. Rubens RD (2000) Clinical aspects of bone metastases. In: Body JJ (ed) Tumor bone diseases and osteoporosis in cancer patients. Marcel Dekker, New York, pp 85-96
2. Cleeland CS, Janjan NA, Scott CB et al (2000) Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys 47:203-208
3. Body JJ (2004) Hypercalcemia of malignancy. Semin Nephrol 24:48-54
4. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97:840-847 (Suppl)
5. Fromigue O, Kheddoumi N, Body JJ (2003) Bisphosphonates antagonize bone growth factors effects on human breast cancer cells survival. Br J Cancer 89:178-184
6. Santini D, Vespasiani Gentilucci U, Vincenzi B et al (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468-1476
7. Kanis JA, Powles T, Paterson AH et al (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667
8. Paterson AHG, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
9. Body JJ, Dumon JC, Piccart M, Ford J (1995) Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 10:1191-1196
10. McCloskey BV, Dunn JA, Kanis JA et al (2001) Long-term follow up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035-1043
11. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701-707
12. Robertson A, Reed N, Ralston S (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13:2427-2430
13. Hortobagyi G, Theriault R, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044
14. Hillner BE, Weeks JC, Desch CE, Smith TJ (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72-79
15. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88:1082-1090
16. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17:846-854
17. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97:848-853 (Suppl)
18. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE (2001) Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433-1438
19. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
20. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744
21. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
22. Rosen L, Gordon D, Tchekmediyan S et al (2004) Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone 34(Suppl 1):S89 (abstract 73)
23. Saad F, Gleason D, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
24. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
25. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962-969
26. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277-4284
27. Lipton A, Seaman J, Zheng M (2004) Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Bone 24(Suppl 1):S62 (abstract 28)
28. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405
29. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133-1137
30. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157-169
31. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (in press)
32. Diel IJ, Body JJ, Lichinitser MR et al (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704-1712
33. Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306-312
34. Coleman R, Rubens R (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
35. Diel IJ, Solomayer EF, Bastert G (2000) Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 1:43-51
36. Body J (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28(Suppl 11):49-53
37. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
38. Zojer N, Keck AV, Pecherstorfer M (1999) Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21:389-406
39. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1679
40. Bell R, Body JJ, Bergström B (2004) Renal safety of intravenous ibandronate for up to 4 years in patients with breast cancer and bone metastases. Breast Cancer Res Treat 88(Suppl 1):S132 (abstract 3058)
41. Neugebauer G, Kohler W, Akinkunmi L et al (2001) Influence of peak ibandronic acid concentrations after 6 mg IV administration with shortened infusion time (15 and 30 minutes) on renal safety in man. Proc Am Soc Clin Oncol 20:122a (abstract 486)
42. Body JJ, Lichinitser M, Andreeva N et al (2004) Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study. Proc Am Soc Clin Oncol 23:60 (abstract 735)
43. Body J, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399-407
44. Kaminski M, Rosen L, Gordon D et al (2004) Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Proc Am Soc Clin Oncol 23:90 (abstract 857)
45. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
46. Mashiba T, Hirano T, Turner CH et al (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
47. Vinholes JJF, Prakash Purohit O, Abbey ME, Eastell R, Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243-1250
48. Lipton A, Costa L, Ali S, Demers L (2001) Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28:54-59
49. Body JJ, Dumon JC, Gineyts E, Delmas PD (1997) Comparative evaluation of markers of bone resorption in patients with breast-cancer induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75:408-412
50. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031-2037
51. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
52. Costa L, Demers LM, Gouveia-Oliveira A et al (2002) Prospective evaluation of the peptide bound collagen type 1 cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850-856
53. Garnero P (2001) Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187-192 (discussion 193-196)
54. De Cock E, Hutton J, Canney P et al (2005) Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer (in press)
55. Berenson J, Hillner B, Kyle R et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncology 20:3719-3736
56. Berenson JR, Vescio R, Henick K et al (2001) A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91:144-154
57. Berenson JR, Vescio RA, Rosen LS et al (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7:478-485
58. Body JJ, Lichinitser M, Tjulandin SA, Budde M, Bergström B (2005) Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. Proc Am Soc Clin Oncol 23:128 (abstract 534)
59. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231-235
60. Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl 5):S270
61. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587-3592
62. Clohisy DR, Mathyh PW (2003) Bone cancer pain. Cancer 97(Suppl 3): 866-873
63. Yau V, Chow E, Davis L et al (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 27:1-3
64. Novartis Pharma. Zometa (zoledronic acid). US prescribing information. November 2004
65. Balla J (2005) The issue of renal safety with zoledronic acid from a nephrologist's point of view. Oncologist 10:306-368
66. Pavlakis N, Stockler M (2002) Bisphosphonates for breast cancer. Cochrane Database System Rev: CD003474
67. Tripathy D, Body JJ, Diel I, Bergstrom B (2004) Intravenous and oral ibandronate reduce the risk of skeletal-related events (SREs) in patients with breast cancer and bone metastases. Eur J Cancer (Suppl 2):138
68. Ernst DS, Brasher P, Hagen N (1997) A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319-326
69. Koeberle D, Bacchus L, Thuerlimann B et al (1999) Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer 7:21-27
70. Ohlmann C, Heidenreich A (2003) Ibandronate in the palliative management of urological malignancies with compensated renal insufficiency. Support Care Cancer 11:413 (abstract A-97)
71. Body JJ, Mancini I, Dumon JC (2004) Intensive intravenous ibandronate treatment significantly relieves opioid-resistant bone pain and improves quality of life in patients with skeletal metastases. Eur J Cancer (Suppl 2):133
72. Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
73. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17
74. Saarto T, Vehmanen L, Blomqvist C et al (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment. Proc Am Soc Clin Oncol 23:8 (abstract 527)
75. Powles T, Paterson S, Kanis J et al (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224
76. Powles T, Paterson A, McCloskey E et al (2004) Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol 23:9 (abstract 528)
77. Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. Proc Am Soc Clin Oncol 23:9 (abstract 529)
78. Kokufu I, Kohno N, Takao S et al (2004) Adjuvant pamidronate therapy for the prevention of bone metastasis in breast cancer patients with four or more positive nodes. Proc Am Soc Clin Oncol 23:8 (abstract 530)
79. Coleman R, Gralow J, Bell R et al (2004) Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer. Bone 34(Suppl 1):S85
80. Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433
81. Powles TJ, McCloskey E, Paterson AH et al (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
82. Vehmanen L, Saarto T, Elomaa I et al (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378
83. Rizzoli R, Forni M, Schaad MA et al (1996) Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 18:531-537
84. Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955-962
85. Gant M, Hausmaninger H, Samonigg H et al (2002) Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+/- zoledronate) as adjuvant treatment for hormone receptor positive pre-menopausal breast cancer: results of a randomised multicenter trial. Breast Cancer Res Treat 76(Suppl 1):S31
86. Theriault R, Jakesz R, Gnant M et al (2004) The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer. Bone 34(Suppl 1): S90
87. Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345:948-955
88. Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012
89. Smith M (2003) Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 20:175-183